Research Article

PEGylated Curcumin Derivative Attenuates Hepatic Steatosis via CREB/PPAR-γ/CD36 Pathway

Yu Liu,1 Fei Cheng,1 Yuxuan Luo,1 Zhu Zhan,1 Peng Hu,1 Hong Ren,1 Huadong Tang,2 and Mingli Peng1

1Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
2Zhejiang University of Technology, Hangzhou 310014, China

Correspondence should be addressed to Mingli Peng; peng_mingli@hospital.cqmu.edu.cn

Received 29 March 2017; Revised 29 May 2017; Accepted 31 May 2017; Published 9 July 2017

Copyright © 2017 Yu Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Curcumin has the potential to cure dyslipidemia and nonalcoholic fatty liver disease (NAFLD). However, its therapeutic effects are curbed by poor bioavailability. Our previous work has shown that modification of curcumin with polyethylene glycol (PEG) improves blood concentration and tissue distribution. This study sought to investigate the role of a novel PEGylated curcumin derivative (Curc-mPEG454) in regulating hepatic lipid metabolism and to elucidate the underlying molecular mechanism in a high-fat-diet-(HFD-)fed C57BL/6J mouse model. Mice were fed either a control chow diet (D12450B), an HFD (D12492) as the NAFLD model, or an HFD with Curc-mPEG454 administered by intraperitoneal injection at 50 mg/kg or 100 mg/kg for 16 weeks. We found that Curc-mPEG454 significantly lowered the body weight and serum triglyceride (TG) levels and reduced liver lipid accumulation in HFD-induced NAFLD mice. It was also shown that Curc-mPEG454 suppressed the HFD-induced upregulated expression of CD36 and hepatic peroxisome proliferator activated receptor-γ (PPAR-γ), a positive regulator of CD36. Moreover, Curc-mPEG454 dramatically activated cAMP response element-binding (CREB) protein, which negatively controls hepatic PPAR-γ expression.

These findings suggest that Curc-mPEG454 reverses HFD-induced hepatic steatosis via the activation of CREB inhibition of the hepatic PPAR-γ/CD36 pathway, which may be an effective therapeutic for high-fat-diet-induced NAFLD.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) has been recognized as the most common chronic hepatic disease and is characterized by increased triglyceride accumulation as lipid droplets in hepatocytes. Obesity, dyslipidemia, hyperuricemia, and insulin resistance enhance the risk of NAFLD, ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis, with prevalence varying from 25% to 40% across different countries [1–3]. At present, there are no approved drugs for the treatment of hepatic lipid metabolism disorder or steatohepatitis by the USA and China Food and Drug Administration [4]. Only OCA (obeticholic acid) has shown promise in improving liver histology, highlighting the urgent need to develop effective therapeutic strategies for NAFLD [5, 6].

Recent advances have focused on several natural polyphenols, such as curcumin, anthocyanins, and resveratrol, which are proposed as promising drug candidates for treatment of NAFLD and possibly future clinical applications [7–9].

Curcumin, a natural polyphenol from turmeric, has been shown to be effective in attenuating liver histopathological changes, reducing cholesterol (TC), triglycerides (TG), and free fatty acid (FFA) levels in the serum and liver, and improving insulin resistance in rodent animals [10–12]. Recently, two randomized double-blind clinical trials, in which NAFLD treatment was performed for 8 weeks, have shown that curcumin significantly lowered the liver fat content, body mass index, and serum levels of TC, TG, low-density lipoprotein cholesterol (LDL-C), glucose, and uric acid compared with the placebo group [13, 14]. These findings suggest that curcumin has the potential to cure dyslipidemia and NAFLD.
However, its therapeutic effects are curbed due to poor bioavailability and very fast systemic elimination [15, 16]. Hence, researchers have made great efforts to improve the bioavailability of curcumin. Modification of a drug with polyethylene glycol (PEG) is a well-known technology for improving the physicochemical properties and biological response of a drug [17]. Moreover, PEG modification has been used to overcome the low aqueous solubility and increase the stability of curcumin [18].

Here, we have produced water-soluble curcumin by conjugating two low-molecular-weight PEGs (mPEG454) via β-thioester bonds (Curc-mPEG454, Figure 1), which had a fixed composition with a curcumin-loading content of 25.3% and released curcumin in the liver. The conjugate retained the biological activities of the native curcumin towards cancer [19]. Therefore, it is reasonable to hypothesize that the curcumin component of Curc-mPEG454 could attenuate lipid metabolism and hepatic steatosis. To investigate the lipiddowering effects of the PEGylated curcumin derivatives and explore the underlying mechanism in treatment of NAFLD, a high-fat-diet (HFD) mouse model was used in this study. Interestingly, we found that Curc-mPEG454 could effectively decrease serum TG levels and attenuate hepatic steatosis via activation of cAMP response element-binding (CREB) protein and subsequent negative inhibition of hepatic-specific peroxisome proliferator activated receptor-γ (PPAR-γ) and fatty acid transporter (CD36) expression. These findings suggest that Curc-mPEG454 has therapeutic potential in NAFLD by regulating lipid metabolism via the CREB/PPAR-γ/CD36 pathway. Our results may direct the use of curcumin for the clinical treatment of NAFLD.

2. Materials and Methods

2.1. Chemical. Amphiphilic curcumin (Curc-mPEG454) was synthesized by Dr. Huadong Tang. Its characterizations are available online at https://www.futuremedicine.com/toc/nnm/5/6. Chloroform, methanol, formalin, and so forth were obtained from the Center of Equipment and Reagent (Chongqing University of Medical Sciences). All the reagents were of analytical quality.

2.2. Animals and Diets. Six-week-old male C57BL/6J mice (Animal Center of Chongqing Medical University, China) were housed in a room at 22°C with a 12-hour light/dark cycle and free access to food and water. After one week of adaption, the mice were randomly divided into four groups of 10 mice each. Control group mice were fed a chow diet (Research Diets, D12492B, 10% cal% fat) and received an intraperitoneal injection of normal saline (NS). The other three groups were fed a high-fat diet (HFD, Research Diets, D12492, 60% cal% fat) supplemented with NS or Curc-mPEG454 (50 or 100 mg/kg) by intraperitoneal injection every other day for 16 weeks. The body weight of each mouse was measured weekly. At the end of the study, the mice were sacrificed after being withdrawn from food for 12 hours. Blood samples were taken by heart puncture to determine the serum biomarkers. The liver was collected and weighed. A portion of liver tissue was either fixed in 4% paraformaldehyde or placed in optimal cutting temperature (OCT) compound (Sakura Finetek, Tokyo, Japan) for histopathological analysis. In addition, the remaining liver tissues were rapidly frozen in liquid nitrogen for gene and protein expression analyses. All animals received humane care that was approved by the Institutional Animal Care and Ethic Committee of Chongqing Medical University.

2.3. Biochemical Parameters. Serum was collected after centrifugation at 1000 rpm for 15 minutes. Serum ALT (CH0101201), AST (CH0101202), TC (CH0101003), TG (CH0101151), HDL-C (CH0101161), LDL-C (CH0101162), and FFA (CH0101157) were measured using routine enzymatic assays using commercial kits (Maccura, Chengdu, China) from HITACHI Clinical Analyzer 7600 (Hitachi, Tokyo, Japan) in the Clinical Laboratory, the Second Affiliated Hospital, Chongqing Medical University.

2.4. Histopathological Analysis. Liver tissues from the same part of each mouse were fixed in 4% paraformaldehyde, embedded in paraffin, sliced, and stained with hematoxylin and eosin (H&E). Fresh livers were fixed in 4% paraformaldehyde, embedded in OCT, and cut into 10 μm thick sections in a cryostat. Frozen sections were stained with 0.2% oil red O. The image analysis software STEPanizer (University of Bern, Switzerland) was used to analyze HE-stained liver tissue digital images. 36 test points (PT) assembled on the image form the point counting (P-C) method (Figure 2(c)). The percentage of area occupied by liver steatosis (Vv) in the image was measured using P-C method. Vv = click on the proportion of fat vesicles (Pp)/the number of 36 test points (PT) [20]. The degree of steatosis was graded as 0–3 based
Figure 2: Curc-mPEG454 reduced hepatic steatosis and hepatic lipid levels after 16-week treatment. Compared with the livers in the chow group, HFD-induced typical steatosis was evidenced by H&E staining (a) and oil red O staining (b) of lipids in representative liver section; a test system containing 36 test points was superimposed on HE-stained images, and the degree of steatosis was assessed by point counting (c), the degree of steatosis of each group (d), and the content of liver TG (e). Curc-mPEG454 treatment significantly reversed the changes. Quantified data are mean ± SD. ***P < 0.001 versus chow group; **P < 0.01 and ###P < 0.001 versus HFD group.

2.5. Hepatic Lipid Measurement. Liver lipids were extracted using the Folch method [22]. Hepatic triglyceride and cholesterol contents were measured using commercial kits (Jiancheng, Nanjing, China). The concentrations of hepatic TG and TC were analyzed and normalized by protein concentration.

2.6. Real-Time PCR and Western Blotting Analysis. Total RNA was extracted from the liver using TRIzol (Invitrogen, USA) according to the manufacturer’s instructions. cDNA
was synthesized with a commercial kit (Takara, Japan). Gene expression was measured by real-time PCR with CFX Connect™ Real-Time PCR System (Bio-Rad, USA). GAPDH was used as an internal control, and the relative expression levels of mRNA were calculated using the 2−ΔΔCt method. The primer pairs used for real-time PCR are listed in Table 1.

For Western blotting, total protein from liver homogenates was lysed using RIPA containing protease inhibitor PhosSTOP (Roche, USA). Protein concentration was determined using a BCA cocktail and the phosphatase inhibitor PhosSTOP (Roche, USA). Protein bands were visualized using ECL (Pierce Rad, USA).

Table 1: Primers to analyze murine genes by real-time PCR.

| Genes      | Accession number | Forward primer                | Reverse primer                |
|------------|------------------|-------------------------------|-------------------------------|
| GAPDH      | GU214026         | 5′-TGACGTGCAGCCTGGAGAAA-3     | 5′-AGTGACCCAAGATGCCCCTTCAG-3' |
| SREBP-1C   | NM_00133979.1    | 5′-GACACACACCAAGACTTGTC-3'    | 5′-GCACACACACCAAGACTTGTC-3'   |
| ACC1       | XM_006539572     | 5′-TAATCTATTTACCTTCCTC-3'     | 5′-TTTCCTTCTTGCCCTCTT-3'      |
| FAS        | NM_007988.3      | 5′-ATGGGTATGCACTGAGAGT-3'     | 5′-ACCACAGAGACCTTATG-3'       |
| SCD-1      | NM_009127.4      | 5′-TCTTTGCGATACACTCTGTC-3'    | 5′-CCGGATGAATGTTTGCTGAT-3'    |
| PPARγ      | NM_001314.1      | 5′-GGGATGTGGTTGAGATCTAG-3'    | 5′-GGCATTTGGACACAGAATG-3'     |
| CPT1α      | NM_003495.2      | 5′-ACGTTGAGAAGATCTGAACA-3'    | 5′-TGTTGACATATCCACTCC-3'      |
| CD36       | NM_031561.2      | 5′-TGGTCAAGCAGCAGTAAA-3'      | 5′-CCCAGTCTTATGACGAC-3'       |
| FABP4      | NM_024406.2      | 5′-AAGTGAGAAGACCTATAACC-3'    | 5′-TCAGCCTTTCTACAACATCC-3'    |
| FATP5      | NM_009512.2      | 5′-TGGATGCTGGGAGATCTAG-3'     | 5′-TTGTGTTTTGCAAGCTTG-3'      |
| DGAT2      | NM_026384.3      | 5′-GGGTGTCAGAGTGTGTTG-3'      | 5′-CAAGAAGAAGTGGAAGGAG-3'     |
| apoB       | NM_009693.2      | 5′-TCPCCGGTGTCTCTTCTTAC-3'    | 5′-CCTCCACAA ACTCTTC-3'       |
| MPT        | NM_008642.2      | 5′-ATCATCATTGAGGCCCTTG-3'     | 5′-CATTCTCCGGGACAC-3'         |
| Cyp7a1      | NM_007824.2      | 5′-GGGCATTTGGAGACACAGATAG-3'  | 5′-ACTCGGTGTAGCAGACAGCATA-3'  |
| LXR        | EU869275         | 5′-TGAAGGCCTGCACACTGAG-3'     | 5′-GGGCTAAGAAGCACCCTATCCT-3'  |
| PXR        | AF031841         | 5′-CGGAGAAGAAGCCGACACT-3'     | 5′-CAGTGTGCGAAGAAGGAG-3'      |
| PPARγ      | NM_00127330      | 5′-GTCACCATATGACGACACC-3'     | 5′-CCCAGTCTGAGCCTAC-3'        |
| PPARγ2     | AB644275.1       | 5′-GGAAGCACCACACTGCTTCTT-3'   | 5′-GTAATCAGAACCATTGGTG-3'     |
| FXR        | NM_001430.8      | 5′-GGCTTCTCTGCGACATCA-3'      | 5′-ACATCAGATGTCCTGAGC-3'      |
| AHR        | NM_00134027.1    | 5′-GCCCAAGACTGTTAGGGTTG-3'    | 5′-TCTGAGGTTGCGACTC-3'        |
| CREB       | NM_001303726.1   | 5′-TGGCAGCTGCTCTTCCATTTAC-3'  | 5′-ATGAGCTGCTGCTTCCATTTAC-3'  |

The primers were designed with Primer 6 and verified by Oligo 7.

2.7. Immunohistochemical Analysis of Liver Steatosis. Immunohistochemistry for CD36 and phospho-CREB was performed using the commercial kit (ZSGB-BIO, China) according to the manufacturer’s instructions. Photographs were captured by a microscope (Nikon, Japan).

2.8. Statistical Analysis. Data were presented as the mean ± standard deviation (SD). Differences between groups were analyzed by one-way ANOVA followed by the Holm-Sidak post hoc test. Statistical significance was considered at P values < 0.05.

3. Results

3.1. Curc-mPEG454 Reduces Body Weight and Plasma TG Level. After 16 weeks of treatment, as shown in Table 2, HFD induced significant elevation of final body weight, body weight gain, and liver weight compared with the chow diet group. Curc-mPEG454 treatment (50 mg/kg and 100 mg/kg) lowered the final body weight and body weight gain compared to the HFD, while there was no dose-dependent difference observed between these two groups. No significant difference in food intake was observed in the four groups, suggesting that the Curc-mPEG454-induced reduction in body weight was not a result of reduced food intake. In addition, we examined the effects of Curc-mPEG454 on serum lipids levels and liver injury. Administration of Curc-mPEG454 significantly lowered plasma TG compared with the HFD but did not affect plasma TC, HLD-C, LDLC, and FFA levels. Further, no difference in serum ALT and AST among the experimental groups was observed, suggesting that Curc-mPEG454 use was safe and did not induce liver
Table 2: Effect of Curc-mPEG454 on body, liver weight, serum lipids, ALT, and AST in high-fat-diet-fed mice.

| Group                  | Chow       | HFD        | HFD + Curc-mPEG454 50 | HFD + Curc-mPEG454 100 |
|------------------------|------------|------------|-----------------------|------------------------|
| Original body weight (g) | 21.30 ± 1.16 | 21.13 ± 0.99 | 21.38 ± 1.19          | 20.55 ± 1.01          |
| Final body weight (g)   | 30.81 ± 2.06 | 44.08 ± 5.44 | 37.64 ± 3.13          | 37.67 ± 4.36          |
| Body weight gain (g)    | 9.51 ± 2.45  | 22.95 ± 5.14 | 16.26 ± 3.42          | 17.12 ± 4.56          |
| Liver weight (g)        | 1.06 ± 0.09  | 1.43 ± 0.28  | 1.35 ± 0.21           | 1.27 ± 0.19           |
| Serum TG (mmol/L)       | 0.67 ± 0.05  | 0.84 ± 0.06  | 0.63 ± 0.12           | 0.61 ± 0.06           |
| Serum TC (mmol/L)       | 2.82 ± 0.06  | 4.17 ± 0.52  | 3.72 ± 0.85           | 3.44 ± 0.87           |
| Serum HDL-C (mmol/L)    | 1.22 ± 0.07  | 1.77 ± 0.39  | 1.68 ± 0.24           | 1.66 ± 0.36           |
| Serum LDL-C (mmol/L)    | 0.39 ± 0.06  | 0.41 ± 0.06  | 0.32 ± 0.08           | 0.28 ± 0.09           |
| Serum FFA level (mmol/L)| 1.05 ± 0.15  | 1.07 ± 0.13  | 1.03 ± 0.14           | 1.19 ± 0.16           |
| Serum ALT level (mmol/L)| 53.75 ± 8.57 | 55.25 ± 10.9 | 40.25 ± 12.66         | 43.75 ± 9.43          |
| Serum AST level (mmol/L)| 128.25 ± 17.80 | 128.75 ± 19.98 | 121.00 ± 18.65        | 112.00 ± 13.14        |

Body weight gain was calculated by the difference between final body weight at the end of the experiments and original body weight. Data are expressed as mean ± SD. * p < 0.05 versus chow and ** p < 0.01 versus chow; # p < 0.05 versus HFD and ## p < 0.01 versus HFD.

injury in vivo. Taken together, these results illustrate that Curc-mPEG454 effectively lowered plasma TG and corrected for hypertriglyceridemia.

3.2. Curc-mPEG454 Attenuates Hepatic Lipid Accumulation.
To assess the impact of Curc-mPEG454 on hepatic steatosis induced by HFD, liver sections were stained with H&E and oil red O to measure hepatic lipid accumulation. As shown in Figures 2(a) and 2(b), mice fed the HFD developed severe macrovesicular and microvesicular steatosis without apparent inflammatory cell infiltration and fibrosis, while there appeared to be an attenuated state of steatosis with notable reduction in the number of vacuolar areas in both Curc-mPEG454 treatment groups. We also measured the percentage of steatosis area by analyzing ten H&E sections with STEPanizer in each group and estimated the degree of steatosis according to Burnt et al. (Figure 2(c)). The results show that the degree of steatosis in the HFD group was mainly distributed in grade 2, while it was significantly attenuated to grades 0 and 1 upon Curc-mPEG454 treatment (Figure 2(d)). Consistent with these results, the TG content in the liver was significantly decreased after Curc-mPEG454 supplementation (Figure 2(e)). In contrast, no obvious change in hepatic TC levels was observed in any of the groups (data not shown). These results indicate that Curc-mPEG454 may effectively protect against hepatic steatosis and TG accumulation induced by HFD.

3.3. Curc-mPEG454 Inhibits HFD-Induced CD36 Expression.
To explore the mechanism underlying the protective effect of Curc-mPEG454 on hepatic steatosis, we assessed for changes in key genes related to lipogenesis, fatty acid uptake, fatty acid oxidation, and TG secretion in liver. Analysis of mRNA expression was presented in Figure 3(a), whereby the mRNA expression of CD36, also named fatty acid transporter (FAT) involved in mediating plasma lipid levels and hepatic fatty acid uptake, was significantly elevated in the HFD and almost restored to normal levels in Curc-mPEG454 (50 and 100 mg/kg) intervention groups. Consistent with observed mRNA expression, the protein level of CD36 was markedly increased with HFD and significantly reduced after treatment with Curc-mPEG454 (50 and 100 mg/kg) (Figures 3(b) and 3(c)), with no significant difference observed between low and high doses of Curc-mPEG454. Immunohistochemistry for CD36 in the liver confirmed that HFD induces higher CD36 membrane exposition of hepatocytes compared to that of the Curc-mPEG454 treated group (Figure 3(d)).

In our study, the level of mRNA expression of genes involved in lipid metabolism, such as sterol regulatory element-binding protein 1C (SREBP-1C), acetyl-CoA carboxylase (ACCI), fatty acid synthase (FAS), and fatty acid transport protein (FATP5), was not affected by HFD treated in the presence or absence of Curc-mPEG454 (Figure 3(a)). These results were inconsistent with a previous study [23] and may be attributed to different diet or drug administration. Since excess liver lipids can be utilized for bile acid synthesis, we examined the expression of genes involved in bile acid synthesis and metabolism. We found that mRNA levels of farnesoid X receptor (FXR) and cholesterol 7-alpha-monoxygenase (Cyp7a1) were unchanged after administration of Curc-mPEG454 (Figure 3(a)). Thus, these results demonstrate that Curc-mPEG454 contributes to improved hepatic steatosis by inhibiting CD36 expression and subsequently reducing FFA uptake and TG synthesis.

3.4. Curc-mPEG454 Specifically Suppresses Hepatic PPAR-γ Expression.
CD36 expression is transcriptionally regulated by several nuclear receptors and transcription factors, such as liver X receptor (LXR), pregnane X receptor (PXR), PPAR-γ [24], FXR [25], and aryl hydrocarbon receptor (AHR) [26]. Moreover, we investigated which of these factors may be involved in Curc-mPEG454 treatment. As shown in Figure 4(a), both hepatic PPAR-γ and PPAR-γ1 were significantly upregulated in the HFD group compared with those in the chow diet group. In addition, the downregulation of PPAR-γ and PPAR-γ1 occurred after Curc-mPEG454 treatment and is consistent with the change in CD36 liver expression. Moreover, there was no significant dose-dependent difference
Figure 3: Effects of Curc-mPEG454 on CD36 expression and hepatic lipid metabolic relative genes in mice after 16-week treatment. qPCR analysis of mRNA levels of genes involved in hepatic lipogenesis, FA oxidation, lipid uptake, TG secretion, and bile acid synthesis (a). Western blot analysis and quantification of CD36 protein; β-actin served as an internal control ((b) and (c)). The immunohistochemical staining of CD36 in liver tissue; the black arrows indicate positive expression of CD36 (d). All figures are representative of at least 3 independent experiments. Quantified date are mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001 versus chow group; ##P < 0.01 and ###P < 0.001 versus HFD group.
3.5. Curc-mPEG454 Activates CREB Phosphorylation. CREB is an upstream molecule that regulates PPAR-γ expression [27] and the cAMP/protein kinase A (PKA)/CREB signaling pathway plays an important role in hepatic lipid metabolism [28]. Therefore, we wondered whether the regulatory effects of Curc-mPEG454 on hepatic steatosis may be via activation of the CREB/PPAR-γ pathway. We found that mRNA and protein expression of CREB in the liver was dramatically downregulated by high-fat diet. Interestingly, Curc-mPEG454 treatment increased both total and phosphorylated CREB levels regardless of the dose used (Figures 5(a), 5(b), and 5(c)). Immunohistochemical studies demonstrated that Curc-mPEG454 treatment activates the immunoreactivity of p-CREB (Figure 5(d)). Hence, our data suggest that Curc-mPEG454 may coordinate hepatic lipids by activating CREB phosphorylation, resulting in the inhibition of PPAR-γ.

4. Discussion

Curcumin improves hepatic lipid metabolism and plasma lipid homeostasis, which consequently lowers the risk of hepatic inflammation and steatosis, diabetes, insulin resistance, and atherosclerosis. However, the poor bioavailability of curcumin compromises its clinical applications. Therefore, improvement of curcumin bioavailability is crucial to its use in clinical applications. Pandey et al. demonstrated that PEG modification can improve the aqueous solubility and
Figure 5: Curc-mPEG454 activated CREB phosphorylation in liver. qPCR analysis of CREB expression (a). Western blot analysis and quantification of phospho-CREB and CREB protein; β-actin served as an internal control ((b) and (c)). The immunohistochemical staining of phospho-CREB in liver tissue (d). All figures are representative of at least 3 independent experiments. Quantified data are the mean ± SD. *$P < 0.05$ and ***$P < 0.001$ versus chow group; †$P < 0.05$ and ###$P < 0.001$ versus HFD group.
bioavailability of curcumin [29]. In this study, we adopted Curc-mPEG454 modified with low-molecular-weight PEG. Previous studies have demonstrated that Curc-mPEG454 produced approximately 50–500 times higher serum curcumin levels than orally, intravenously, or intraperitoneally administered curcumin [19]. In the current study, we found that the mice treatment with Curc-mPEG454 at dose of 50 mg/kg could achieve similar lipid-lowering effects as 1000 mg/kg curcumin treatment in Zingg’s research [28]. Therefore, we speculate that PEGylation improves the pharmacokinetics and pharmacodynamics of curcumin. Moreover, Curc-mPEG454 exhibits better bioactivity than parent curcumin. We also found that there was no difference between the two doses of Curc-mPEG454 used in our study. Therefore, we speculate that Curc-mPEG454 at dose of 50 mg/kg has reached an effective serum concentration and that increasing the drug dose will not enhance its curative effects.

The imbalance between FFA input and output in the liver leads to TG deposition and hepatic steatosis. The major sources of FFA in the liver were diet supplementation, de novo synthesis in the liver, and adipose tissue decomposition. The massive FFA in liver can be metabolized via β-oxidation in mitochondria, esterified to formation of TG and storage in lipid droplets, or combined with apolipoproteins and secreted into blood through VLDL [30]. In this study, we found that Curc-mPEG454 treatment significantly downregulated HFD-induced hepatic CD36 expression and then reduced the hepatic FFA uptake from the peripheral circulation FFA. Moreover, we observed no impact on genes involved in lipogenesis, beta-oxidation, TG secretion, and bile acid metabolism. CD36 functions as a transporter mediating liver long-chain FFA uptake and esterification, which regulates the development of hepatic steatosis [31]. Clinical studies have shown that dysregulated expression of hepatic CD36 was significantly associated with insulin resistance, hyperinsulinemia, and increased steatosis in patients with NAFLD and chronic hepatitis C [32]. Elevated expression of CD36 was also observed in mouse models with genetic obesity and high-fat-feeding-induced fatty livers [33]. Therefore, therapeutic strategies aimed at reversing this process by restoring normal CD36 levels may provide a new approach to therapy for NAFLD.

CD36 is a shared target of LXR, PXR, PPAR-γ [24], FXR [25], and AHR [26] when mediating lipid homeostasis. Nuclear receptors and transcription factors establish a cross-talk network regulating the homeostasis of bile acids, lipid, glucose, inflammation, vitamins, hormones, and others [34]. In the present study, we prove that Curc-mPEG454 specifically reduces the expression of hepatic PPAR-γ, which is originally described as a transcriptional factor crucial for controlling lipid homeostasis [35, 36]. Furthermore, hepatocyte-specific PPAR-γ expression is positively associated with fatty liver in mouse models. For instance, overexpression of PPAR-γ leads to hepatic steatosis and hepatocyte-specific knockout of PPAR-γ reduces hepatic fat content in HFD-fed mice [37, 38]. Taken together, the protective effects of Curc-mPEG454 against hepatic steatosis are possibly via specific inhibition of PPAR-γ/CD36 pathway activation and subsequent reduction of FFA uptake and TG synthesis in the liver.

CREB, an upstream molecular target of PPAR-γ, is a transcription factor that plays an important role in gluconeogenesis and fatty acid oxidation [39–41]. Herzig’s research found that CREB inhibits hepatic TG synthesis and storage during fasting via PPAR-γ repression and demonstrated that mice infected with a dominant-negative CREB-expressing adenovirus progressed into fatty liver with increased hepatic TG content consistent with elevated hepatic PPAR-γ and CD36 expression [27]. Inoue et al. reported that CREB expression in liver was significantly suppressed by high-fat diet and CREB/PPAR-γ signaling pathways may be involved in HFD-induced hepatic steatosis [35]. A recent study revealed that curcumin may contribute to its hypolipidemic effect by increasing cAMP levels and the phosphorylation of CREB in LDL−/− mice fed an HFD [28]. Based on these findings, we raise a hypothesis that Curc-mPEG454 controls hepatic metabolism through CREB negative regulation of PPAR-γ. Our results showed that Curc-mPEG454 dramatically activated CREB phosphorylation consistent with decreased PPAR-γ. Hence, we speculate that activation of the hepatic CREB/PPAR-γ/CD36 pathway by Curc-mPEG454 is crucial for reducing lipid accumulation in liver (Figure 6).
In summary, our study demonstrates that Curc-mPEG454 possesses protective effects against dyslipidemia and fatty liver, similar to curcumin. In addition, our findings provide new insight into the mechanism underlying curcumin-mediated fatty liver. Hence, PEGylated curcumin has better bioavailability and can be used as a promising candidate for NAFLD therapy.

**Abbreviations**

ACCoA: Acetyl-CoA carboxylase  
AHR: Aryl hydrocarbon receptor  
ALT: Alanine aminotransferase  
AST: Aspartate aminotransferase  
CREB: cAMP response element-binding  
FATP: Fatty acid transport protein  
FAS: Fatty acid synthase  
FFA: Free fatty acid  
FXR: Farnesoid X receptor  
H&E: Hematoxylin and eosin  
HDL-C: High-density lipoprotein cholesterol  
HFD: High-fat diet  
LDL-C: Low-density lipoprotein cholesterol  
LXR: Liver X receptor  
NAFLD: Nonalcoholic fatty liver disease  
NASH: Nonalcoholic steatohepatitis  
PEG: Polyethylene glycol  
PKA: cAMP/protein kinase A  
PXR: Pregnan X receptor  
SREBP: Sterol regulatory element-binding protein  
TC: Cholesterol  
TG: Triglycerides.

**Disclosure**

Yu Liu and Fei Cheng are co-first authors.

**Conflicts of Interest**

The authors declare that there are no conflicts of interest.

**Authors’ Contributions**

Mingli Peng and Yu Liu were responsible for the design of this study. Yu Liu, Fei Cheng, and Yuxuan Luo performed the experiments; all authors participated in data analysis and interpretation. Yu Liu, Mingli Peng, Fei Cheng, and Zhu Zhan contributed to manuscript writing. Yu Liu and Fei Cheng contributed equally to this work.

**Acknowledgments**

This work was supported by grants from the National Natural Science Foundation of China (no. 30771921) and the National Science and Technology Major Project of China (2012ZX1002007-001 and 2017ZX102203-008).

**References**

[1] L. Serfaty and M. Lemoine, “Definition and natural history of metabolic steatosis: Clinical aspects of nafl, nash and cirrhosis,” *Diabetes and Metabolism*, vol. 34, no. 6, pp. 634–637, 2008.

[2] G. Vernon, A. Baranova, and Z. M. Younossi, “Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults,” *Alimentary Pharmacology and Therapeutics*, vol. 34, no. 3, pp. 274–285, 2011.

[3] G. C. Farrell, V. W.-S. Wong, and S. Chitturi, “NAFLD in Asia—as common and important as in the West,” *Nature Reviews Gastroenterology and Hepatology*, vol. 10, no. 5, pp. 307–318, 2013.

[4] G. Musso, M. Cassader, F. Rosina, and R. Gambino, “Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials,” *Diabetologia*, vol. 55, no. 4, pp. 885–904, 2012.

[5] G. Musso, M. Cassader, and R. Gambino, “Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies,” *Nature Reviews Drug Discovery*, vol. 15, no. 4, pp. 249–274, 2016.

[6] B. Hameed and N. Terrault, “Emerging Therapies for Nonalcoholic Fatty Liver Disease,” *Clinics in Liver Disease*, vol. 20, no. 2, pp. 365–385, 2016.

[7] F. Salomone, J. Godos, and S. Zelber-Sagi, “Natural antioxidants for non-alcoholic fatty liver disease: Molecular targets and clinical perspectives,” *Liver International*, vol. 36, no. 1, pp. 5–20, 2016.

[8] H. Yao, Y.-J. Qiao, Y.-L. Zhao et al., “Herbal medicines and non-alcoholic fatty liver disease,” *World Journal of Gastroenterology*, vol. 22, no. 30, pp. 6890–6905, 2016.

[9] H. Song, T. Wu, D. Xu, Q. Chu, D. Lin, and X. Zheng, “Dietary sweet cherry anthocyanins attenuates diet-induced hepatic steatosis by improving hepatic lipid metabolism in mice,” *Nutrition*, vol. 32, no. 7–8, pp. 827–833, 2016.

[10] W. Shao, Z. Yu, Y. Chiang et al., “Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes,” *PLoS ONE*, vol. 7, no. 1, Article ID e28874, 2012.

[11] Y. Öner-liyidoglan, H. Koçak, M. Seyidhanoglu et al., “Curcumin prevents liver fat accumulation and serum fetuin-A increase in rats fed a high-fat diet,” *Journal of Physiology and Biochemistry*, vol. 69, no. 4, pp. 677–686, 2013.

[12] E.-M. Jang, M.-S. Choi, U. J. Jung et al., “Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat—fed hamsters,” *Metabolism*, vol. 57, no. 11, pp. 1576–1583, 2008.

[13] Y. Panahi, P. Kianpour, R. Mohtashami, R. Jafari, L. E. Simental-Mendiá, and A. Sahebkar, “Curcumin lowers serum lipids and uric acid in subjects with nonalcoholic fatty liver disease: a randomized controlled trial,” *Journal of Cardiovascular Pharmacology*, vol. 68, no. 3, pp. 223–229, 2016.

[14] S. Rahmani, S. Asgary, G. Askari et al., “Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial,” *Phytotherapy Research*, vol. 30, no. 9, pp. 1540–1548, 2016.

[15] A. Sahebkar, “Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?” *BioFactors*, vol. 39, no. 2, pp. 197–208, 2013.
M. Catta-Preta, L. S. Mendonca, J. Fraulob-Aquino, M. B. J. C. Cohen, J. D. Horton, and H. H. Hobbs, "Human fatty liver metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis," *American Journal of Gastroenterology*, vol. 111, no. 6, pp. 1519–1523, 2016.

M. E. Miquilena-Colina, E. Lima-Cabello, S. Sánchez-Campos et al., "Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C," *Gut*, vol. 60, no. 10, pp. 1394–1402, 2011.

D. Greco, A. Kotronen, J. Westerbacka et al., "Gene expression in human NAFLD," *The American Journal of Physiology: Gastrointestinal and Liver Physiology*, vol. 294, no. 5, pp. G1281–G1287, 2008.

J.-M. Pascussi, S. Gerbal-Chaloin, C. Duret, M. Daujat-Chavanieu, M.-J. Vilarem, and P. Maurel, "The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences," *Annual Review of Pharmacology and Toxicology*, vol. 48, pp. 1–32, 2008.

M. Inoue, T. Ohtake, W. Motomura et al., "Increased expression of PPARγ in high fat diet-induced liver steatosis in mice," *Biochemical and Biophysical Research Communications*, vol. 336, no. 1, pp. 215–222, 2005.

M. Ahmadian, J. M. Suh, N. Hah et al., "PPARγ signaling and metabolism: the good, the bad and the future," *Nature Medicine*, vol. 19, no. 5, pp. 557–566, 2013.

A. Wolf Greenstein, N. Majumdar, P. Yang, P. V. Subbaiah, R. D. Kineman, and J. Cordoba-Chacon, "Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice," *Journal of Endocrinology*, vol. 232, no. 1, pp. 107–121, 2016.

E. Morán-Salvador, M. López-Parra, V. García-Alonso et al., "Role for PPARγ and PPARβ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts," *The FASEB Journal*, vol. 25, no. 8, pp. 2538–2550, 2011.

P. Puigserver, J. Rhee, J. Donovan et al., "Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1α interaction," *Nature*, vol. 423, no. 6939, pp. 550–555, 2003.

J. C. Yoon, P. Puigserver, G. Chen et al., "Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1," *Nature*, vol. 413, no. 6852, pp. 131–138, 2001.

S. Herzig, F. Long, U. S. Jhala et al., "CREB regulates hepatic gluconeogenesis through the coactivator PGC-1," *Nature*, vol. 413, no. 6852, pp. 179–183, 2001.